An Open-Label, Randomized, 3-Way Crossover, Single-Dose Study in Healthy Volunteers Comparing the Bioavailability of CMX001 (HDP-Cidofovir Conjugate) Delivered as a Tablet Formulation vs a Solution Formulation and the Effect of Food on CMX001 Bioavailability.
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2014
At a glance
- Drugs Brincidofovir (Primary) ; Brincidofovir (Primary)
- Indications Cytomegalovirus infections; Herpes simplex virus infections; Human papillomavirus infections; Human polyomavirus infections; Smallpox
- Focus Pharmacokinetics
- 03 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Nov 2008 New trial record.